The global GLP-1 analogues market was valued at US$ 51.6 Billion in 2024 and is projected to reach US$ 211.8 Billion by 2035, expanding at a compound annual growth rate (CAGR) of 13.7% during the forecast period from 2025 to 2035. The market is witnessing remarkable growth due to the rising prevalence of type 2 diabetes and obesity, increasing demand for advanced metabolic therapies, growing...